SC
ONCE

Steven Cohen’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Steven Cohen’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$8.28M – 1324
2018
Q2 		$8.28M Buy
+100,000
New +$7.72M 0.03% 483

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Steven Cohen's ONCE Position: Q2 2019 in Review

Steven Cohen sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 100,000 shares — an estimated $11.4M sold.

Steven Cohen first reported a position in ONCE in Q2 2017 and held it in 5 quarters. The position peaked at $11.4M in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Steven Cohen reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Steven Cohen sold 100,000 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $11.4M.
  • Steven Cohen first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2017 and held it in 5 quarters.
  • Steven Cohen's Spark Therapeutics, Inc. Common Stock position peaked at $11.4M in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Point72 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.